Caracterización de los pacientes diabéticos y prediabéticos portadores de VIH en hospital terciario de Concepción / Characterization of diabetic and prediabetic patients carriying of HIV in a tertiary hospital in Concepcion

The increased survival of patients with Human Immunodeficiency Virus (HIV), due in great part to antiretroviral therapy, has led to the disease becoming a chronic condition. The result of this new picture, is the development of several chronic metabolic diseases, including diabetes mellitus. The aim of this retrospective study is to evaluate the prevalence of diabetes mellitus and prediabetes in HIV people that is controlled in a tertiary Chilean hospital and other epidemiological aspects of this condition. The results show a prevalence of 2.95 percent of diabetes and 13.0 percent of prediabetes in HIV patients, similar results to the international literature. The vast majority of these patients acquire diabetes or prediabetes after the HIV debut. It is important to know our local prevalence of metabolic comorbidities in these patients, in this case diabetes and prediabetes, to improve our research and adequate treatment in this population.

Impacto de la inmunodepresión basal y su grado de recuperación al año de terapia antirretroviral en sobrevida, complicaciones oportunistas y reacción de recuperación inmune / Impact of baseline CD4 count, immune recoveny and viral suppression at 7 year of first highly active antiretroviral therapy on survival, AIDS defining events and immune recovery reactions

Background: Baseline (BL) CD4 cell count is a major factor in outcome of highly active antiretroviral therapy (HAART); treatment induced immune recovery and viral response can modulate this outcome. Aim: To evaluate the association between baseline CD4 cell count and outcome during the first HAART régimen. Material and methods: Prospective study in 2,050 patients on first HAART with a follow up (f/u) ofat least 1 year. All had BL CD4 and viral load (VL) counts which were repeated at least twice a year. Patients were grouped according to BL CD4 (cells/mm³) in <100 (Gl), 100-199 (G2) and ≥ (G3). Groups were further divided according to immune and vírologícal response at 1 year in CD4 > or < 200 and VL detectable or undetectable (<80 copies/mL). Outcome measures were death, ALUS defining events (ADE) and, as a surrogate marker of immune recovery reaction, herpes zoster (HZ). Resulte: During the first year of follow up, 113 patients (10.8 percent) diedin Gl (n =1,044), 17 (2.5 percent) in G2 (n =675) (Gl-2 p <0.05) and 9 (2.7 percent) in G3 (n =331) (G2-3 p NS). One hundred twenty five of919 (13.6 percent) patients alive at 1 year had ADE in Gl, 55/643 (8.5 percent) in G2 (p <0.05) and 20/320 (5.2 percent) in G3 (G2-3 p NS). ADEs with follow up CD4 >vs< 200 were: 25/274 (9.1 percent) vs 100/643 (15 7 percent) in Gl (p <0.005); 28/404 (6.9 percent) vs 27/235 (11.2 percent) in G2 (p NS) and 18/281 (6.4 percent) vs 2/41 (4.8 percent) in G3 respectively (p NS). Detectable VL was an additional risk for ADE only in Gl without CD4 recovery. HZ was seen in 6.6 percent of Gl vs 4 percent in G2 (p <0.05) and 4.3 percent in G3. HZ rate was higher in all groups reaching a follow up CD4 >200 than those who did not, with a statistically significant difference at p <0.05 only in Gl (9.5 percent vs 5.3 percent). Conclusions: The occurrence of death and ADE during the first year of HAART was significantly higher in patients with aBL CD4...